"But we want to go further [with] reforms that will address the research sector's need for a more risk-proportionate regulatory framework for clinical trials and will help get cutting-edge new ...

BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy.